Cargando…
Therapeutic concentrations of glucagon-like peptide-1 in cerebrospinal fluid following cell-based delivery into the cerebral ventricles of cats
BACKGROUND: Neuropeptides may have considerable potential in the treatment of acute and chronic neurological diseases. Encapsulated genetically engineered cells have been suggested as a means for sustained local delivery of such peptides to the brain. In our experiments, we studied human mesenchymal...
Autores principales: | Glage, Silke, Klinge, Petra M, Miller, Miles C, Wallrapp, Christine, Geigle, Peter, Hedrich, Hans J, Brinker, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3114785/ https://www.ncbi.nlm.nih.gov/pubmed/21575271 http://dx.doi.org/10.1186/2045-8118-8-18 |
Ejemplares similares
-
A new look at cerebrospinal fluid circulation
por: Brinker, Thomas, et al.
Publicado: (2014) -
Microglial downregulation in a double transgenic mouse model associated with early-onset Alzheimer's disease (AD) after intraventricular implantation of alginate encapsulated Glukagon-like-peptide-1 (GLP-1) producing human mesenchymal stem-cells
por: Harmening, Kathrin, et al.
Publicado: (2009) -
Multiplicity of cerebrospinal fluid functions: New challenges in health and disease
por: Johanson, Conrad E, et al.
Publicado: (2008) -
Anidulafungin and Micafungin Concentrations in Cerebrospinal Fluid and in Cerebral Cortex
por: Marx, Jana, et al.
Publicado: (2020) -
A theoretical investigation on the geometries of glucagon-like peptide-1 and its interactions with dipeptidyl peptidase DPP-IV
por: Brickmann, Jürgen, et al.
Publicado: (2008)